Sequenom (SQNM) Shares are Up 174.1%

Sequenom (SQNM) : Traders are bullish on Sequenom (SQNM) as it has outperformed the S&P 500 by a wide margin of 153.7% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 174.28%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 174.1% in the last 1 week, and is up 162.22% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 129.68% and the 50-Day Moving Average is 123.78%. Sequenom Inc. is up 84.38% in the last 3-month period. Year-to-Date the stock performance stands at 43.9%.


Sequenom (NASDAQ:SQNM): On Fridays trading session , Opening price of the stock was $2.36 with an intraday high of $2.37. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $2.36. However, the stock managed to close at $2.36, a loss of 0.42% for the day. On the previous day, the stock had closed at $2.37. The total traded volume of the day was 2,352,404 shares.

Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *